Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/09/20
Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdatesBusiness Wire • 11/09/20
Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative ColitisBusiness Wire • 11/06/20
Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020Business Wire • 11/02/20
Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D.Business Wire • 10/22/20
Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting Business Wire • 10/12/20
Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics SummitBusiness Wire • 09/22/20
Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study ResultsBusiness Wire • 09/11/20
Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common StockBusiness Wire • 08/17/20
Tiny Biotech Follows Big Stock Jump With Stock Offering Pricing; MCRB SlipsInvestors Business Daily • 08/13/20
Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common StockBusiness Wire • 08/13/20
Seres Therapeutics Skyrockets On Positive Pivotal Study Results For Microbiome TherapeuticBenzinga • 08/10/20
Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infectionsMarket Watch • 08/10/20
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile InfectionBusiness Wire • 08/10/20
Do Options Traders Know Something About Seres Therapeutics (MCRB) Stock We Don't?Zacks Investment Research • 08/07/20